Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...

Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

Women with Crohn’s disease may experience additional symptoms along with typical Crohn’s disease symptoms. Knowing what to expect can help you prepare for these and find ways to get relief.

A study published today in the American Journal of Gastroenterology reveals significant disparities in healthcare utilization ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Take Steps is the Crohn’s & Colitis Foundation’s signature fundraising event. This year (2025), the event will take place at Citizen’s Bank Park on May 9th. Funds raised at Take Steps ...

In patients with Crohn's disease and intermediate to high preoperative corticosteroid use, primary ileocaecal resection leads ...

Crohn’s disease and ulcerative colitis are both inflammatory bowel diseases with similar symptoms. However, some key differences include the areas they affect, diagnostic tools, and treatment plans.

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...